Summary
Estradiol 3-Benzoate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypothyroidism would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypothyroidism. ClinicalTrials.gov lists 1 registered trial linking Estradiol 3-Benzoate to Hypothyroidism: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 300 participants. Registered activity dates to 2023. No published literature item is linked to Estradiol 3-Benzoate and Hypothyroidism in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Hypothyroidism ranks 81 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Hashimoto's (most common cause) is irreversible in majority; spontaneous recovery in <5%; subclinical hypothyroidism spontaneously normalizes in ~30-40% of cases within 2 years without treatment.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 22.5 (trials 2.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | CAMK4 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05782725 | Subclinical Hypothyroidism and Normogonadotropic Anovulation 2023 | completed | Not applicable | 300 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CAMK4. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Estradiol 3-Benzoate approved for Hypothyroidism?
Estradiol 3-Benzoate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypothyroidism would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypothyroidism. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Estradiol 3-Benzoate in clinical trials for Hypothyroidism?
ClinicalTrials.gov lists 1 registered trial linking Estradiol 3-Benzoate to Hypothyroidism: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 300 participants. Registered activity dates to 2023.
What does the evidence show for Estradiol 3-Benzoate in Hypothyroidism?
Estradiol 3-Benzoate has 1 completed registered trial for Hypothyroidism but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CAMK4. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.